New combo shrinks tumors before surgery in major cancer trial
NCT ID NCT06279130
First seen Mar 08, 2026 · Last updated May 08, 2026 · Updated 10 times
Summary
This study tests two immunotherapy drugs, botensilimab and balstilimab, given before surgery to people with certain solid tumors that can be removed. The goal is to see if the drugs can shrink or eliminate the tumor before surgery. About 133 adults with either mismatch repair deficient (dMMR) or mismatch repair proficient (pMMR) cancers will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESECTABLE MMR-DEFICIENT SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Netherlands Cancer Institute
RECRUITINGAmsterdam, North Holland, 1066 CX, Netherlands
Contact
Contact
Conditions
Explore the condition pages connected to this study.